Similar articles

• Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

  Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Li AC, et al. J Clin Invest. 2000 Aug;106(4):523-31. doi: 10.1172/JCI10370. J Clin Invest. 2000. PMID: 10953027 Free PMC article.
• [Anti-atherosclerotic effects of PPAR gamma ligands].

  Wakino S. Wakino S. Nihon Rinsho. 2004 Jan;62(1):180-6. Nihon Rinsho. 2004. PMID: 14737851 Review. Japanese.
• PPAR gamma: an essential role in metabolic control.

  Fajas L, Debril MB, Auwerx J. Fajas L, et al. Nutr Metab Cardiovasc Dis. 2001 Feb;11(1):64-9. Nutr Metab Cardiovasc Dis. 2001. PMID: 11383325 Review.
• Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation.

  de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, Little PJ. de Dios ST, et al. Circulation. 2003 May 27;107(20):2548-50. doi: 10.1161/01.CIR.0000074040.31731.96. Epub 2003 May 12. Circulation. 2003. PMID: 12742988
• Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.

  Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD. Berger J, et al. Endocrinology. 1996 Oct;137(10):4189-95. doi: 10.1210/endo.137.10.8828476. Endocrinology. 1996. PMID: 8828476